» Medarex, Inc. Announces Initiation of Phase 2 <b>Clinical Trials</b> for <b>...</b>
(Nasdaq: MEDX - News) announced today that it has initiated the Phase 2 clinical development program of MDX-1100, a fully human monoclonal antibody that targets CXCL10 (also known as IP-10), in…